AIRLINK 204.45 Increased By ▲ 3.55 (1.77%)
BOP 10.09 Decreased By ▼ -0.06 (-0.59%)
CNERGY 6.91 Increased By ▲ 0.03 (0.44%)
FCCL 34.83 Increased By ▲ 0.74 (2.17%)
FFL 17.21 Increased By ▲ 0.23 (1.35%)
FLYNG 24.52 Increased By ▲ 0.48 (2%)
HUBC 137.40 Increased By ▲ 5.70 (4.33%)
HUMNL 13.82 Increased By ▲ 0.06 (0.44%)
KEL 4.91 Increased By ▲ 0.10 (2.08%)
KOSM 6.70 No Change ▼ 0.00 (0%)
MLCF 44.31 Increased By ▲ 0.98 (2.26%)
OGDC 221.91 Increased By ▲ 3.16 (1.44%)
PACE 7.09 Increased By ▲ 0.11 (1.58%)
PAEL 42.97 Increased By ▲ 1.43 (3.44%)
PIAHCLA 17.08 Increased By ▲ 0.01 (0.06%)
PIBTL 8.59 Decreased By ▼ -0.06 (-0.69%)
POWER 9.02 Decreased By ▼ -0.09 (-0.99%)
PPL 190.60 Increased By ▲ 3.48 (1.86%)
PRL 43.04 Increased By ▲ 0.98 (2.33%)
PTC 25.04 Increased By ▲ 0.05 (0.2%)
SEARL 106.41 Increased By ▲ 6.11 (6.09%)
SILK 1.02 Increased By ▲ 0.01 (0.99%)
SSGC 42.91 Increased By ▲ 0.58 (1.37%)
SYM 18.31 Increased By ▲ 0.33 (1.84%)
TELE 9.14 Increased By ▲ 0.03 (0.33%)
TPLP 13.11 Increased By ▲ 0.18 (1.39%)
TRG 68.13 Decreased By ▼ -0.22 (-0.32%)
WAVESAPP 10.24 Decreased By ▼ -0.05 (-0.49%)
WTL 1.87 Increased By ▲ 0.01 (0.54%)
YOUW 4.09 Decreased By ▼ -0.04 (-0.97%)
BR100 12,137 Increased By 188.4 (1.58%)
BR30 37,146 Increased By 778.3 (2.14%)
KSE100 115,272 Increased By 1435.3 (1.26%)
KSE30 36,311 Increased By 549.3 (1.54%)

ROME: A top official in the European Medicines Agency said it might be worth abandoning AstraZeneca’s coronavirus vaccine for all age groups where alternatives are available, in an interview published Sunday.

Marco Cavaleri, the EMA’s head of vaccine strategy, also told Italy’s La Stampa newspaper that the Johnson & Johnson jab should be preferentially used for the over 60s.

Both so-called viral vector vaccines are authorised for everyone over 18 but have been dogged by reports of rare blood clots. The EU has also authorised two mRNA vaccines, Pfizer/BioNTech and Moderna.

Italy on Saturday restricted AstraZeneca vaccines to people aged 60 and over following concerns about the heightened health risks for younger people.

Asked if it would not be better to ban AstraZeneca including for the over 60s, Cavaleri said: “Yes, and it is an option that many countries, such as France and Germany, are considering in the light of the increased availability of mRNA vaccines.

“However, incidents were very rare and after the first dose. It is true that there is less data on the second dose, but in the United Kingdom it (the vaccination programme) is going well.”

He added: “Among young people the risks of illness decrease, and the message for them could be to use preferentially the mRNA vaccines, but the choice is left to individual states.”

Comments

Comments are closed.